Loading stock…

Torrent Pharmaceuticals Limited (500420) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Torrent Pharmaceuticals Limited

500420Market cap $19BPrice $49.6

Country🇮🇳India

SectorHealthcare

IndustryPharmaceuticals

Manufactures and markets branded generic drugs across cardiovascular, diabetes, and CNS therapies, dominating India's cardiac and diabetology prescription market. One of the country's top pharma players, it also runs a growing presence in Brazil and Germany.

In Bastion Portfolios?

52W Return+23%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+9%6

Revenue Forecast

Rev CAGR (1y)+37%9

Rev CAGR (3y)+21%9

Rev CAGR (5y)+15%9

Earnings Forecast

EPS Growth Y+1-2%3

EPS Growth Y+2+38%9

EPS Growth Y+3+33%9

Quality

Margins

EBIT Margin23%8

Net Income Margin14%7

Free Cash Flow Margin15%7

Debt

Net Debt/EBITDA2.63

Efficiency

ROE27%9

ROAna–

Earnings Stability77

GEAR+STRONG85

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)731

P/E Ratio (Forward 3y)401

P/BV21.71

EV Multiples

EV/EBITDA Fwd301

EV/EBIT Fwd471

Yield

Free Cash Flow Yield1.3%3

Dividend Yieldna–

Momentum

Short term

1 month return-3%6

3 month return-2%6

YTD return+25%8

Mid term

Price vs 52wHigh91%8

1 year return+35%8

Long term

3 year return+158%9

5 year return+228%9

Risk Shield

Price Risk

Beta0.39

Volatility22%9

Free Cash Flow

Free Cash Flow Margin15%7

Free Cash Flow Yield1.3%3

Quality

ROCE20%9

Earnings Stability77

Net Debt/EBITDA2.63

02Growth

Is it actually growing, and how fast?

500420Torrent Pharmaceuticals

Revenue FY26$1.5B

GROWTH RATING↗

VERY STRONG86 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y+37%9

Revenue, next 3Y, CAGR+21%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E-2%3

EPS growth, FY28E+38%9

EPS growth, FY29E+33%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 86% of companies worldwide.

Revenue is set to grow 21%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 9%/yr over the last 3 years and is set to grow 21%/yr from here.

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

WATCH

Earnings are set to grow faster than sales (EPS about 33%/yr vs revenue 21%/yr), so margins should widen. One year dips: EPS falls 2% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up. The one thing to watch: the earnings path has a down year.

03Price Momentum

Is the market behind it right now?

500420Torrent Pharmaceuticals

Total return Current358%

Price return Current315%

MOMENTUM RATING↗

STRONG82 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-2%6

YTD return+25%8

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+35%8

3-year return+158%9

5-year return+228%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +158% over three years and +228% over five, ahead of 80% of the market.

It's up 35% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+25%).

WATCH

Returns sit at the market level over the past month (-3%) and over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns and the stock sits near its highs. A reliable trend, if not the single hottest name in the market.

04Value

Are you paying a fair price for it?

Stop guessing on Torrent Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

500420Torrent Pharmaceuticals

Revenue FY26$1.5B

GROWTH RATING↗

VERY STRONG86 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y+37%9

Revenue, next 3Y, CAGR+21%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY27E-2%3

EPS growth, FY28E+38%9

EPS growth, FY29E+33%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 86% of companies worldwide.

Revenue is set to grow 21%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 9%/yr over the last 3 years and is set to grow 21%/yr from here.

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

WATCH

Earnings are set to grow faster than sales (EPS about 33%/yr vs revenue 21%/yr), so margins should widen. One year dips: EPS falls 2% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up. The one thing to watch: the earnings path has a down year.

03Price Momentum

Is the market behind it right now?

500420Torrent Pharmaceuticals

Total return Current358%

Price return Current315%

MOMENTUM RATING↗

STRONG82 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return-2%6

YTD return+25%8

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+35%8

3-year return+158%9

5-year return+228%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +158% over three years and +228% over five, ahead of 80% of the market.

It's up 35% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+25%).

WATCH

Returns sit at the market level over the past month (-3%) and over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns and the stock sits near its highs. A reliable trend, if not the single hottest name in the market.

04Value

Are you paying a fair price for it?

Stop guessing on Torrent Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community